Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Hematology · Myelodysplastic Syndrome with Ring Sideroblasts

Your Future Outlook: Risk and Monitoring

At a Glance

MDS-SF3B1 (formerly MDS-RS) is a slow-moving bone marrow condition with a generally favorable prognosis. Doctors use the IPSS-M scoring system, which includes your genetic profile, to determine your specific risk. For most patients, it acts as a manageable chronic illness requiring regular blood monitoring.

Predicting the future of a medical condition can be daunting, but with Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS/MDS-SF3B1), the tools for understanding your outlook are more precise than ever. While this is a chronic bone marrow condition, it is typically characterized by its slow progression and “favorable” behavior compared to other forms of MDS [1][2].

The IPSS-M: Your Molecular Roadmap

For years, doctors used a system called the IPSS-R to predict how MDS might behave. Today, we have a more advanced version: the IPSS-M (Molecular International Prognostic Scoring System) [3].

The IPSS-M is essentially a sophisticated calculator that combines your blood counts and bone marrow findings with your genetic profile [4]. By including the specific “typos” (mutations) in your DNA, the IPSS-M can provide a much more personalized risk score. It categorizes patients into groups ranging from “Very Low” to “Very High” risk [3][5]. For most people with the SF3B1 mutation and low blast counts, the score falls into the Low or Very Low risk categories [1][6].

Why SF3B1 is a “Favorable” Marker

In the world of MDS, the SF3B1 mutation is considered a positive sign for several reasons:

  • Slow Disease Course: It is strongly associated with an indolent (slow-moving) disease that focuses primarily on anemia rather than more aggressive problems [1].
  • Low Transformation Risk: Compared to other subtypes, MDS-SF3B1 has a significantly lower risk of turning into Acute Myeloid Leukemia (AML) [2][7].
  • Survival Rates: For most patients, “longer overall survival” means that this disease will act as a manageable chronic condition. Many patients go on to live a near-normal lifespan for their age group, rather than facing the rapidly shortened life expectancy associated with acute leukemias [8][2].

The Role of “Co-Mutations”

While SF3B1 is generally favorable, it does not act alone. Your IPSS-M score also looks for co-mutations—other genetic changes that might appear alongside it [9].

  • Neutral Partners: Some mutations, like DNMT3A, do not seem to change the good outlook of SF3B1 [10].
  • Caution Flags: Other mutations, such as ASXL1 or RUNX1, can sometimes “upgrade” the risk level, making the disease act more aggressively [11].

The TP53 Exception: The TP53 mutation is more than just a caution flag. If this mutation is present, it fundamentally alters the disease biology, overriding the favorable nature of SF3B1. It shifts the diagnosis to a high-risk category (often called MDS-TP53) requiring a completely different, more aggressive treatment approach [12]. This is why a full molecular profile is now considered mandatory for accurate risk scoring [13].

Life with MDS: The Surveillance Schedule

Because this is a chronic condition, “surveillance” (monitoring) is your most important tool. While schedules are personalized, they generally follow these principles:

  • CBC Monitoring: You will likely need a Complete Blood Count (CBC) every few months to check your hemoglobin, white cells, and platelets. Sudden changes in these numbers are more important than a single low reading [14].
  • Bone Marrow Assessments: Repeat bone marrow biopsies are not usually done on a strict schedule if your blood counts are stable. They are typically reserved for times when there is a significant change in your blood work or symptoms [15].
  • Symptom Awareness: Vigilance for new symptoms like unexplained fevers, weight loss, or unusual bruising is essential, as these can be signs that the disease is changing [16].

A Reassuring Fact: Most patients with MDS-SF3B1 will manage their condition as a chronic illness for many years, focusing on maintaining energy levels rather than fighting an aggressive cancer [17][18].

Common questions in this guide

What is the IPSS-M score for MDS?
The Molecular International Prognostic Scoring System (IPSS-M) is a tool that combines your blood counts, bone marrow results, and genetic profile. It calculates a personalized risk score to predict how your myelodysplastic syndrome will behave over time.
Is the SF3B1 mutation in MDS a good or bad sign?
The SF3B1 mutation is generally considered a favorable sign in myelodysplastic syndrome. It is usually associated with a slow-moving disease focused on anemia, with a lower risk of transforming into acute myeloid leukemia.
What happens if I have a TP53 mutation with MDS-SF3B1?
Having a TP53 mutation changes the behavior of the disease, making it more high-risk and aggressive. This mutation overrides the favorable nature of SF3B1 and typically requires a completely different treatment approach.
How often will I need a bone marrow biopsy?
If your routine blood counts remain stable, repeat bone marrow biopsies are not usually done on a strict schedule. They are typically reserved for times when there are significant changes in your blood work or if you develop new symptoms.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific risk category according to the IPSS-M (Molecular IPSS)?
  2. 2.Does my molecular report show any high-risk 'co-mutations' like ASXL1, RUNX1, or TP53 alongside my SF3B1 mutation?
  3. 3.Based on my low-risk status, how often do I need a CBC and when should we consider a repeat bone marrow biopsy?
  4. 4.What is my specific risk of this condition progressing to AML over the next 5 to 10 years?
  5. 5.How do my results compare to the typical 'favorable' outlook for SF3B1-mutated MDS?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    New Subtype Proposed for Myelodysplastic Syndrome.

    American journal of medical genetics. Part A 2020; (182(8)):1854-1855 doi:10.1002/ajmg.a.61238.

    PMID: 33043582
  2. 2

    SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia.

    Xiong B, Xue M, Yu Y, et al.

    Clinical lymphoma, myeloma & leukemia 2020; (20(5)):329-339.e3 doi:10.1016/j.clml.2020.01.005.

    PMID: 32037286
  3. 3

    How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome.

    Xian RR

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):51-58 doi:10.1182/hematology.2023000420.

    PMID: 38066895
  4. 4

    Risk stratifying MDS in the time of precision medicine.

    Cazzola M

    Hematology. American Society of Hematology. Education Program 2022; (2022(1)):375-381 doi:10.1182/hematology.2022000349.

    PMID: 36485160
  5. 5

    Validation and comparison of the molecular international prognostic scoring system (IPSS-M) and the revised international prognostic scoring system (IPSS-R) in myelodysplastic neoplasms (MDS): a retrospective study.

    Hu M, Zhou M, Shen Y, et al.

    Hematology (Amsterdam, Netherlands) 2025; (30(1)):2479257 doi:10.1080/16078454.2025.2479257.

    PMID: 40094267
  6. 6

    Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes.

    Komrokji R, Volpe V, Chan O, et al.

    Blood 2021; (138(11)):989-992 doi:10.1182/blood.2021010831.

    PMID: 34036300
  7. 7

    Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.

    Shingai N, Harada Y, Iizuka H, et al.

    International journal of hematology 2018; (108(6)):598-606 doi:10.1007/s12185-018-2551-y.

    PMID: 30353274
  8. 8

    SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates.

    Loscocco GG, Guglielmelli P, Mannelli F, et al.

    American journal of hematology 2022; (97(9)):E347-E349 doi:10.1002/ajh.26648.

    PMID: 35796725
  9. 9

    Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.

    Aqil B, Sukhanova M, Behdad A, et al.

    Human pathology 2022; (129()):81-89 doi:10.1016/j.humpath.2022.08.007.

    PMID: 36087739
  10. 10

    Comparison of SF3B1/DNMT3A Comutations With DNMT3A or SF3B1 Mutation Alone in Myelodysplastic Syndrome and Clonal Cytopenia of Undetermined Significance.

    Song J, Hussaini M, Qin D, et al.

    American journal of clinical pathology 2020; (154(1)):48-56 doi:10.1093/ajcp/aqaa016.

    PMID: 32112088
  11. 11

    Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.

    Bernard E, Tuechler H, Greenberg PL, et al.

    NEJM evidence 2022; (1(7)):EVIDoa2200008 doi:10.1056/EVIDoa2200008.

    PMID: 38319256
  12. 12

    Case Report: Myelodysplastic/myeloproliferative neoplasm with concurrent SF3B1, ASXL1, JAK2 and CBL mutations and <15% bone marrow ringed sideroblasts.

    Wang Y, Jin S

    Frontiers in oncology 2025; (15()):1622820 doi:10.3389/fonc.2025.1622820.

    PMID: 40772034
  13. 13

    Updates in low/intermediate-risk MDS.

    Carraway HE

    Hematology. American Society of Hematology. Education Program 2025; (2025(1)):699-708 doi:10.1182/hematology.2025000768.

    PMID: 41348013
  14. 14

    Therapy for lower-risk MDS.

    Carraway HE, Saygin C

    Hematology. American Society of Hematology. Education Program 2020; (2020(1)):426-433 doi:10.1182/hematology.2020000127.

    PMID: 33275714
  15. 15

    NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.

    Greenberg PL, Stone RM, Abaza Y, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2025; (23(3)):66-75 doi:10.6004/jnccn.2025.0013.

    PMID: 40073835
  16. 16

    Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists.

    Madanat YF, Zeidan AM

    Clinics in laboratory medicine 2023; (43(4)):685-698 doi:10.1016/j.cll.2023.07.003.

    PMID: 37865511
  17. 17

    Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM).

    Jouzier C, Cherait A, Cony-Makhoul P, et al.

    Transfusion 2022; (62(5)):961-973 doi:10.1111/trf.16884.

    PMID: 35452143
  18. 18

    The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome

    Rujirachaivej P, Siriboonpiputtana T, Rerkamnuaychoke B, et al.

    Asian Pacific journal of cancer prevention : APJCP 2018; (19(7)):1825-1831 doi:10.22034/APJCP.2018.19.7.1825.

    PMID: 30049194

This information about MDS-SF3B1 prognosis and IPSS-M scoring is for educational purposes only. Always consult your hematologist to understand your specific risk category and monitoring schedule.

Get notified when new evidence is published on Acquired idiopathic sideroblastic anemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.